Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Change in Accured Expenses (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Change in Accured Expenses data on record, last reported at -$1.6 million in Q4 2020.

  • For Q4 2020, Change in Accured Expenses rose 72.43% year-over-year to -$1.6 million; the TTM value through Dec 2020 reached $2.7 million, changed N/A, while the annual FY2024 figure was -$28.9 million, 1048.96% down from the prior year.
  • Change in Accured Expenses reached -$1.6 million in Q4 2020 per KLRS's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.6 million in Q3 2020 and bottomed at -$5.7 million in Q4 2019.